Validation of the International Prognostic Index in Working Formulation group A low-grade non-Hodgkin's lymphoma: Retrospective analysis of 137 patients from the Gruppo Italiano per lo Studio dei Linfomi registry

Caterina Stelitano, Luca Baldini, Carla Pieresca, Vincenzo Callea, Francesco Angrilli, Vera Clò, Giovanni Partesotti, Francesco Merli, Luigi Cavanna, Fortunato Morabito, Massimo Federico, Maura Brugiatelli, Vittorio Silingardi

Research output: Contribution to journalArticle

Abstract

Background and Objectives. The subset of non-follicular non-Hodgkin's lymphoma (NHL) includes patients with varied prognoses, thus suitable for different therapeutic approaches. The International Prognostic Index (IPI), originally proposed for aggressive NHL, has been demonstrated to be of prognostic relevance also in follicular NHL. The main aim of the study was to validate the IPI in this histologic category; in addition, the specific prognostic classification, currently employed in the Gruppo Italiano per lo Studio dei Linfomi (GISL) prospective therapeutic trials and based on different features, more similar to those applied to chronic lymphocytic leukemia, was analyzed. Design and Methods. The present series consists of 137 evaluable patients affected by Working Formulation group A NHL out of 256 cases referred to the GISL Registry. The retrospective prognostic study included the evaluation by both univariate and multivariate analyses of overall survival, response to therapy and response duration. The IPI was applied as originally proposed. The GISL definition of indolent and aggressive disease at diagnosis was based on the presence of B symptoms, bulky disease, anemia and thrombocytopenia. Results. The distribution of patients in IPI risk groups was rather unbalanced with 18%, 47%, 28% and 7% of cases classified as low (L), intermediated-low (IL), intermediate-high (IH) and high (H) risk, respectively. The median overall survival was not reached in either L or IL risk groups, and was 84.1 and 7.4 months for IH and H risk groups, respectively (p=0.0005). A simplified IPI model was designed merging patients in both intermediate risk groups and the statistical difference of survival retained its significance. GISL prognostic stratification was demonstrated to have a significant association with survival, with a median survival of 71.3 months in aggressive disease and a median survival not reached at 152 months in indolent disease. Both the simplified IPI model and the GISL risk definition retained their significance in multivariate analysis for overall survival, while for response to therapy only the simplified IPI model resulted to be of statistical significance. In addition, the GISL prognostic stratification identified patients with different outcomes within the IPI intermediate risk group, with a median survival of 70.2 months for patients with aggressive disease whereas the median survival for those with indolent disease was not reached. Finally, a prognostic score resulting from the integration of the simplified IPI and the GISL system was statistically validated. Interpretation and Conclusions. The retrospective analysis of this series demonstrates the validity of the IPI in non-follicular indolent NHL and the usefulness of integrating the IPI parameters with disease specific prognostic variables. (C) 2000, Ferrata Storti Foundation.

Original languageEnglish
Pages (from-to)154-159
Number of pages6
JournalHaematologica
Volume85
Issue number2
Publication statusPublished - Feb 2000

Fingerprint

Non-Hodgkin's Lymphoma
Registries
Survival
Multivariate Analysis
Follicular Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Therapeutics
Thrombocytopenia
Anemia
Retrospective Studies

Keywords

  • International Prognostic Index
  • Non-Hodgkin's lymphoma
  • Prognosis
  • Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Validation of the International Prognostic Index in Working Formulation group A low-grade non-Hodgkin's lymphoma : Retrospective analysis of 137 patients from the Gruppo Italiano per lo Studio dei Linfomi registry. / Stelitano, Caterina; Baldini, Luca; Pieresca, Carla; Callea, Vincenzo; Angrilli, Francesco; Clò, Vera; Partesotti, Giovanni; Merli, Francesco; Cavanna, Luigi; Morabito, Fortunato; Federico, Massimo; Brugiatelli, Maura; Silingardi, Vittorio.

In: Haematologica, Vol. 85, No. 2, 02.2000, p. 154-159.

Research output: Contribution to journalArticle

Stelitano, C, Baldini, L, Pieresca, C, Callea, V, Angrilli, F, Clò, V, Partesotti, G, Merli, F, Cavanna, L, Morabito, F, Federico, M, Brugiatelli, M & Silingardi, V 2000, 'Validation of the International Prognostic Index in Working Formulation group A low-grade non-Hodgkin's lymphoma: Retrospective analysis of 137 patients from the Gruppo Italiano per lo Studio dei Linfomi registry', Haematologica, vol. 85, no. 2, pp. 154-159.
Stelitano, Caterina ; Baldini, Luca ; Pieresca, Carla ; Callea, Vincenzo ; Angrilli, Francesco ; Clò, Vera ; Partesotti, Giovanni ; Merli, Francesco ; Cavanna, Luigi ; Morabito, Fortunato ; Federico, Massimo ; Brugiatelli, Maura ; Silingardi, Vittorio. / Validation of the International Prognostic Index in Working Formulation group A low-grade non-Hodgkin's lymphoma : Retrospective analysis of 137 patients from the Gruppo Italiano per lo Studio dei Linfomi registry. In: Haematologica. 2000 ; Vol. 85, No. 2. pp. 154-159.
@article{8fb37f2299824db089ddcbb351b04cda,
title = "Validation of the International Prognostic Index in Working Formulation group A low-grade non-Hodgkin's lymphoma: Retrospective analysis of 137 patients from the Gruppo Italiano per lo Studio dei Linfomi registry",
abstract = "Background and Objectives. The subset of non-follicular non-Hodgkin's lymphoma (NHL) includes patients with varied prognoses, thus suitable for different therapeutic approaches. The International Prognostic Index (IPI), originally proposed for aggressive NHL, has been demonstrated to be of prognostic relevance also in follicular NHL. The main aim of the study was to validate the IPI in this histologic category; in addition, the specific prognostic classification, currently employed in the Gruppo Italiano per lo Studio dei Linfomi (GISL) prospective therapeutic trials and based on different features, more similar to those applied to chronic lymphocytic leukemia, was analyzed. Design and Methods. The present series consists of 137 evaluable patients affected by Working Formulation group A NHL out of 256 cases referred to the GISL Registry. The retrospective prognostic study included the evaluation by both univariate and multivariate analyses of overall survival, response to therapy and response duration. The IPI was applied as originally proposed. The GISL definition of indolent and aggressive disease at diagnosis was based on the presence of B symptoms, bulky disease, anemia and thrombocytopenia. Results. The distribution of patients in IPI risk groups was rather unbalanced with 18{\%}, 47{\%}, 28{\%} and 7{\%} of cases classified as low (L), intermediated-low (IL), intermediate-high (IH) and high (H) risk, respectively. The median overall survival was not reached in either L or IL risk groups, and was 84.1 and 7.4 months for IH and H risk groups, respectively (p=0.0005). A simplified IPI model was designed merging patients in both intermediate risk groups and the statistical difference of survival retained its significance. GISL prognostic stratification was demonstrated to have a significant association with survival, with a median survival of 71.3 months in aggressive disease and a median survival not reached at 152 months in indolent disease. Both the simplified IPI model and the GISL risk definition retained their significance in multivariate analysis for overall survival, while for response to therapy only the simplified IPI model resulted to be of statistical significance. In addition, the GISL prognostic stratification identified patients with different outcomes within the IPI intermediate risk group, with a median survival of 70.2 months for patients with aggressive disease whereas the median survival for those with indolent disease was not reached. Finally, a prognostic score resulting from the integration of the simplified IPI and the GISL system was statistically validated. Interpretation and Conclusions. The retrospective analysis of this series demonstrates the validity of the IPI in non-follicular indolent NHL and the usefulness of integrating the IPI parameters with disease specific prognostic variables. (C) 2000, Ferrata Storti Foundation.",
keywords = "International Prognostic Index, Non-Hodgkin's lymphoma, Prognosis, Survival",
author = "Caterina Stelitano and Luca Baldini and Carla Pieresca and Vincenzo Callea and Francesco Angrilli and Vera Cl{\`o} and Giovanni Partesotti and Francesco Merli and Luigi Cavanna and Fortunato Morabito and Massimo Federico and Maura Brugiatelli and Vittorio Silingardi",
year = "2000",
month = "2",
language = "English",
volume = "85",
pages = "154--159",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "2",

}

TY - JOUR

T1 - Validation of the International Prognostic Index in Working Formulation group A low-grade non-Hodgkin's lymphoma

T2 - Retrospective analysis of 137 patients from the Gruppo Italiano per lo Studio dei Linfomi registry

AU - Stelitano, Caterina

AU - Baldini, Luca

AU - Pieresca, Carla

AU - Callea, Vincenzo

AU - Angrilli, Francesco

AU - Clò, Vera

AU - Partesotti, Giovanni

AU - Merli, Francesco

AU - Cavanna, Luigi

AU - Morabito, Fortunato

AU - Federico, Massimo

AU - Brugiatelli, Maura

AU - Silingardi, Vittorio

PY - 2000/2

Y1 - 2000/2

N2 - Background and Objectives. The subset of non-follicular non-Hodgkin's lymphoma (NHL) includes patients with varied prognoses, thus suitable for different therapeutic approaches. The International Prognostic Index (IPI), originally proposed for aggressive NHL, has been demonstrated to be of prognostic relevance also in follicular NHL. The main aim of the study was to validate the IPI in this histologic category; in addition, the specific prognostic classification, currently employed in the Gruppo Italiano per lo Studio dei Linfomi (GISL) prospective therapeutic trials and based on different features, more similar to those applied to chronic lymphocytic leukemia, was analyzed. Design and Methods. The present series consists of 137 evaluable patients affected by Working Formulation group A NHL out of 256 cases referred to the GISL Registry. The retrospective prognostic study included the evaluation by both univariate and multivariate analyses of overall survival, response to therapy and response duration. The IPI was applied as originally proposed. The GISL definition of indolent and aggressive disease at diagnosis was based on the presence of B symptoms, bulky disease, anemia and thrombocytopenia. Results. The distribution of patients in IPI risk groups was rather unbalanced with 18%, 47%, 28% and 7% of cases classified as low (L), intermediated-low (IL), intermediate-high (IH) and high (H) risk, respectively. The median overall survival was not reached in either L or IL risk groups, and was 84.1 and 7.4 months for IH and H risk groups, respectively (p=0.0005). A simplified IPI model was designed merging patients in both intermediate risk groups and the statistical difference of survival retained its significance. GISL prognostic stratification was demonstrated to have a significant association with survival, with a median survival of 71.3 months in aggressive disease and a median survival not reached at 152 months in indolent disease. Both the simplified IPI model and the GISL risk definition retained their significance in multivariate analysis for overall survival, while for response to therapy only the simplified IPI model resulted to be of statistical significance. In addition, the GISL prognostic stratification identified patients with different outcomes within the IPI intermediate risk group, with a median survival of 70.2 months for patients with aggressive disease whereas the median survival for those with indolent disease was not reached. Finally, a prognostic score resulting from the integration of the simplified IPI and the GISL system was statistically validated. Interpretation and Conclusions. The retrospective analysis of this series demonstrates the validity of the IPI in non-follicular indolent NHL and the usefulness of integrating the IPI parameters with disease specific prognostic variables. (C) 2000, Ferrata Storti Foundation.

AB - Background and Objectives. The subset of non-follicular non-Hodgkin's lymphoma (NHL) includes patients with varied prognoses, thus suitable for different therapeutic approaches. The International Prognostic Index (IPI), originally proposed for aggressive NHL, has been demonstrated to be of prognostic relevance also in follicular NHL. The main aim of the study was to validate the IPI in this histologic category; in addition, the specific prognostic classification, currently employed in the Gruppo Italiano per lo Studio dei Linfomi (GISL) prospective therapeutic trials and based on different features, more similar to those applied to chronic lymphocytic leukemia, was analyzed. Design and Methods. The present series consists of 137 evaluable patients affected by Working Formulation group A NHL out of 256 cases referred to the GISL Registry. The retrospective prognostic study included the evaluation by both univariate and multivariate analyses of overall survival, response to therapy and response duration. The IPI was applied as originally proposed. The GISL definition of indolent and aggressive disease at diagnosis was based on the presence of B symptoms, bulky disease, anemia and thrombocytopenia. Results. The distribution of patients in IPI risk groups was rather unbalanced with 18%, 47%, 28% and 7% of cases classified as low (L), intermediated-low (IL), intermediate-high (IH) and high (H) risk, respectively. The median overall survival was not reached in either L or IL risk groups, and was 84.1 and 7.4 months for IH and H risk groups, respectively (p=0.0005). A simplified IPI model was designed merging patients in both intermediate risk groups and the statistical difference of survival retained its significance. GISL prognostic stratification was demonstrated to have a significant association with survival, with a median survival of 71.3 months in aggressive disease and a median survival not reached at 152 months in indolent disease. Both the simplified IPI model and the GISL risk definition retained their significance in multivariate analysis for overall survival, while for response to therapy only the simplified IPI model resulted to be of statistical significance. In addition, the GISL prognostic stratification identified patients with different outcomes within the IPI intermediate risk group, with a median survival of 70.2 months for patients with aggressive disease whereas the median survival for those with indolent disease was not reached. Finally, a prognostic score resulting from the integration of the simplified IPI and the GISL system was statistically validated. Interpretation and Conclusions. The retrospective analysis of this series demonstrates the validity of the IPI in non-follicular indolent NHL and the usefulness of integrating the IPI parameters with disease specific prognostic variables. (C) 2000, Ferrata Storti Foundation.

KW - International Prognostic Index

KW - Non-Hodgkin's lymphoma

KW - Prognosis

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0034039979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034039979&partnerID=8YFLogxK

M3 - Article

C2 - 10681722

AN - SCOPUS:0034039979

VL - 85

SP - 154

EP - 159

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 2

ER -